IS RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT IN MYELODYSPLASTIC SYNDROMES WORTHWHILE

被引:17
作者
SPIRITI, MAA
PETTI, MC
LATAGLIATA, R
AVVISATI, G
DEGREGORIS, C
PROIA, S
FAZI, P
JAALOUK, G
MANCINI, M
SPADEA, A
VILLA, R
MANDELLI, F
机构
[1] Haematology, Department of Human Biopathology, University La Sapienza of Rome
[2] Haematology, Department of Human Biopathology, Cilag Spa, Medical Direction Milano
关键词
MYELODYSPLASTIC SYNDROMES; ERYTHROPOIETIN;
D O I
10.3109/10428199309148507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been recently demonstrated that erythropoietin increases the haemoglobin levels in anemia secondary to chronic renal failure. Moreover some recent experiences also suggested a possible role in the treatment of MDS. From April 1990 to April 1992, 23 patients (16 males and 7 females, median age 63.5 years) affected with low risk myelodysplastic syndrome (MDS) were treated with recombinant human erythropoietin (rHuEPO) to ameliorate Hb levels and transfusional requirement. All patients received high doses of rHuEPO (800 U/Kg weekly s.c. in 2-3 divided doses, for 3 months). A complete remission, defined as stable normalization of Hb level, was achieved in 1/23 patients. This patient had refractory anemia, by FAB criteria. A partial response, defined as stable increase of Hb levels greater-than-or-equal-to 1g/dl and/or reduction of transfusional requirement greater-than-or-equal-to 50% lasting at least 3 months, was achieved in 7/23 patients. Patients with a partial response received rHuEPO at increased dosages (1200 U/Kg weekly s.c. 2-3 times): 1/7 achieved a complete response, 4/7 remained stable and 2/7 decreased to pre-therapy Hb value. These results suggest that rHuEPO may be a promising therapeutic tool for some MDS patients.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 20 条
[1]  
Appelbaum F.R., Storb B., Ramberg R.E., Shulman H.M., Buckner C.D., Clift R.A., Deeg H.J., Fefer A., Sanders J., Self S., Swiger J., Stewart P., Sullivan K., Witherspoon R., Thomas E.D., Treatment of preleukemic syndromes with marrow transplantation, Blood, 69, pp. 92-96, (1987)
[2]  
Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E., Structural characterization of human erythropoietin, J. Biol. Chem., 261, pp. 3116-3121, (1986)
[3]  
Eschbach J.W., The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin, Kidney Int., 35, pp. 134-148, (1989)
[4]  
Ludwig H., Fritz E., Kotzman H., Hocker F., Gisslinger H., Barnas U., Erythropoietin treatment of anemia associated with multiple myeloma, N. Eng. J. Med., 31, pp. 1693-1699, (1990)
[5]  
Aoki I., Chikazawa H., Higashi K., Ishikawa K., In vitro effects of high titers of recombinant human erythropoietin on the bone marrow erythroid progenitors in patients with aplastic anemia, Jpn. J. Clin. Hematol., 30, pp. 437-442, (1989)
[6]  
Bowen D.T., Jacobs A., Mary P., Cotes P.M., Lewis T.C., Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes, Eur. J. Haematol., 44, pp. 30-32, (1990)
[7]  
Besa E.C., Nathan F., Sylvester L., Catalano P., Erythroid response of severely anemic or transfusion-dependent patients with myelodysplastic syndrome to recombinant human erythropoietin (EPO) does not correlate with baseline serum EPO levels, Blood, 76, (1990)
[8]  
Garcia J.F., Ebbe S.N., Hollander L., Cutting H.O., Miller M.E., Cronkite E.P., Radioimmunoassay of erythropoietin: circulating levels in normal and polycytemic human beings, J. Lab. Clin. Med., 99, pp. 624-635, (1982)
[9]  
Schuster M.W., Allen S.L., Lichtman S.M., Schulman P., De Marco L.C., Budman D.R., Muuse W.T., The use of erythropoietin in the treatment of myelodysplastic syndrome and myelofibrosis, Proc. Am. Soc. Clin. Oncol., (1990)
[10]  
Hoelzer D., Ganser A., Seipelt G., Ottman O., Hoffken K., Boogaerts M., Verhaef G., Lutz D., Krieger O., De Witte T., Diehl W., Lathan B., Ferrant A., Martiat P., Klausmann M., Ganghl D., Frisch J., Schultz G., Hemopoietic growth factors (HGF) in the treatment of patients with myelodysplastic syndromes, Proc. Am. Soc. Clin. Oncol., (1990)